Influence of clinical features on the health status of patients with limited cutaneous systemic sclerosis
- 31 May 2006
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 55 (3) , 473-479
- https://doi.org/10.1002/art.21999
Abstract
Objective To determine the effect of limited cutaneous systemic sclerosis (lcSSc) on patients' health status, and to identify the contributions to health status of different manifestations of lcSSc. Methods The Short Form 36 questionnaire was completed by 213 patients with lcSSc or Raynaud's syndrome and an antinuclear antibody typical of lcSSc as part of the baseline visit of the Quinapril in Scleroderma trial. Results were analyzed after correcting for age and sex using the Welsh Health Survey. Patients' results were related to their clinical characteristics. Results The mean physical component score (PCS) was 44.0 (95% confidence interval [95% CI] 42.5, 45.5), which was lower than the population norm of 50, and the median mental component score (MCS) was 52.2 (95% CI 48.5, 54.3). Raynaud's disease visual analog scale (VAS) scores, lung function, the number of organ systems affected, and skin score were significantly correlated with PCS. The total score (TDS) of an SSc severity scale showed the highest correlation. The effect of lcSSc on PCS was worse in younger patients. Multiple regression including age demonstrated that Raynaud's disease severity could predict a reduction in PCS beyond that predicted by TDS. Raynaud's disease severity and duration of lcSSc were linked to low MCS. Arthritis reduced PCS and esophageal involvement reduced PCS and MCS. Conclusion Physical health status of patients with lcSSc was reduced, with 30% of the variation predicted by TDS, age, and severity of Raynaud's disease VAS. Mental health status was not reduced in this population.Keywords
This publication has 26 references indexed in Scilit:
- The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse sclerodermaRheumatology, 2003
- Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibitionRheumatology, 2002
- Surgery for ischemic pain and Raynaud's' phenomenon in scleroderma: A description of treatment protocol and evaluation of resultsMicrosurgery, 2001
- Extended extracorporeal photochemotherapy with extracorporeal administration of 8‐methoxypsoralen in systemic sclerosis. An Austrian single‐center studyPhotodermatology, Photoimmunology & Photomedicine, 2000
- Prediction of five-year survival following presentation with scleroderma: Development of a simple model using three disease factors at first visitArthritis & Rheumatism, 1999
- Development and validation of a self-administered systemic sclerosis questionnaire (SySQ)Rheumatology, 1999
- Skin involvement as a relevant outcome measure in clinical trials of systemic sclerosisCurrent Opinion in Rheumatology, 1997
- Concurrent validity of the health assessment questionnaire disability index in sclerodermaArthritis & Rheumatism, 1995
- RELIABILITY OF SKIN INVOLVEMENT MEASURES IN SCLERODERMARheumatology, 1992
- Nutritional Support in Patients with Systemic SclerodermaJournal of Parenteral and Enteral Nutrition, 1989